Condition
APL
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
75%
3 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 2 (1)
P 3 (2)
P 4 (1)
Trial Status
Recruiting2
Not Yet Recruiting1
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07503730Phase 3RecruitingPrimary
Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).
NCT07296445Phase 3Not Yet Recruiting
A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)
NCT05881265Phase 2RecruitingPrimary
Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia
NCT02020161Phase 4UnknownPrimary
Clinical Guidelines for APL Treatment
Showing all 4 trials